Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Stephen Falk"'
Autor:
Jakob R. Izbicki, Gary Middleton, Alan Anthoney, Paula Ghaneh, Harpreet Wasan, Kinnari Patel, David Cunningham, Olusola Olusesan Faluyi, Rubin Soomal, Thilo Hackert, John P. Neoptolemos, Christopher Halloran, Derek A. O'Reilly, Alec McDonald, Jonathan Wadsley, Yuk Ting Ma, Eftychia E. Psarelli, David Sherriff, Pascal Hammel, Markus W. Büchler, David Borg, Bengt Glimelius, Juan W. Valle, Roopinder Gillmore, Sharmila Sothi, Pehr Lind, Daniel H. Palmer, Tom Crosby, Tim Meyer, Richard J. Jackson, Paul Ross, Suzanne Darby, Stephen Falk, Sebastian Cummins
Publikováno v:
Lancet
Lancet (London, England)
European Study Group for Pancreatic Cancer 2017, ' Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. ', The Lancet, vol. 389, no. 10073, pp. 1011-1024 . https://doi.org/10.1016/S0140-6736(16)32409-6
Lancet (London, England)
European Study Group for Pancreatic Cancer 2017, ' Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. ', The Lancet, vol. 389, no. 10073, pp. 1011-1024 . https://doi.org/10.1016/S0140-6736(16)32409-6
Summary Background The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials